POMPANO BEACH, Fla.--(BUSINESS WIRE)--Stimwave LLC, a medical device manufacturer and independent research institute headquartered in South Florida, announced today that Paul LaViolette, managing ...
Hosted on MSN
Pulse Biosciences targets Q1 completion of PRECISE-BTN study enrollment as clinical adoption grows
CEO Paul LaViolette highlighted significant momentum across Pulse Biosciences’ three market development programs, emphasizing early adoption and progress in clinical trials. LaViolette stated, "We are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback